Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tegoprazan - CJ Healthcare/RaQualia Pharma

Drug Profile

Tegoprazan - CJ Healthcare/RaQualia Pharma

Alternative Names: CJ-12420; K-CAB; LXI-15028; RQ-00000004; RQ-4

Latest Information Update: 10 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer CJ Cheiljedang Corp.; CJ HealthCare; RaQualia Pharma; Shandong Luoxin Pharmaceutical
  • Class Amides; Anti-inflammatories; Antibacterials; Antiulcers; Benzimidazoles; Benzopyrans; Fluorobenzenes; Small molecules
  • Mechanism of Action H(+) K(+)-exchanging ATPase inhibitors; Potassium-competitive acid blockers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Erosive oesophagitis; Gastro-oesophageal reflux
  • Phase III Gastric ulcer; Helicobacter infections

Most Recent Events

  • 08 Jan 2020 CJ HealthCare Corporation plans a phase-I drug-drug interaction trial in healthy volunteers in South Korea (PO, Tablet) (NCT04221321)
  • 29 Nov 2019 Tegoprazan licensed to CJ HealthCare in Europe, North America and USA
  • 26 Nov 2019 CJ HealthCare plans a clinical trial in USA in December 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top